TytoCare Raises $25M+ to Scale AI-First Virtual Care

TytoCare raised $25M+ in a growth round and appointed Adam Pellegrini as CEO. The New York-based remote physical examination company is using the financing to scale AI-powered virtual primary care infrastructure, including FDA-cleared remote examination devices and AI-powered software supporting clinical decision-making.

Healthcare has spent the last decade proving patients will talk to doctors through a screen. TytoCare is chasing the harder layer: whether enough of the physical exam can move into the home for clinicians to make better remote decisions. That matters because virtual care is no longer fighting for novelty; it is fighting for clinical confidence.

What Happened

According to the company's July 15, 2026 announcement, TytoCare closed a $25M+ growth financing round led by Insight Partners, with participation from existing strategic investors including Healthcare of Ontario Pension Plan, OliveTree, OrbiMed, Qumra Capital, Qualcomm Ventures, and others.

The company also appointed Adam Pellegrini as CEO, bringing in a digital health operator with more than 2 decades of experience across consumer health technology, clinical programs, and scaled care delivery. Co-founded by Dedi Gilad and Ofer Tzadik, the company continues to benefit from the founders' involvement, with Gilad now serving as co-founder and board member.

The financing follows TytoCare's earlier rounds, including a $49M financing announced in 2023 and previous later-stage investments led or backed by Insight Partners. The newest round is more than another milestone in the company's funding history. It arrives as TytoCare positions itself around AI-first clinical enablement, an approach that ultimately has to produce better remote examinations, stronger clinician confidence, and more effective care pathways beyond the clinic.

Why This Matters

Telehealth solved access, but access alone does not make a virtual visit clinically useful. TytoCare's thesis is that remote care requires better inputs: heart sounds, lung sounds, ear examinations, skin images, throat assessments, abdominal evaluations, and AI-supported guidance that helps clinicians evaluate patients without pretending a webcam is a stethoscope.

That is the difference between video conferencing and healthcare infrastructure. TytoCare combines handheld, clinician-grade remote examination devices with FDA-cleared AI-powered Software as a Medical Device algorithms through products such as Tyto Insights, giving health systems and payers a more robust toolkit for virtual primary care, cardiopulmonary monitoring, oncology support, and complex chronic disease management.

Market Context

Healthcare AI is moving from administrative automation toward clinical decision support, and that shift raises the standard. A model that writes a clinical note can be valuable; a platform that supports diagnosis, examinations, and patient pathways requires regulatory evidence, physician trust, workflow integration, and patient safety within the same ecosystem.

TytoCare has spent years building in that more demanding segment of the market. Its platform sits at the intersection of remote patient monitoring, virtual primary care, medical device regulation, and AI diagnostics. Capital can accelerate that roadmap, but it cannot instantly create the regulatory credibility and clinical deployment history companies need as virtual care moves closer to diagnosis.

Competitive Landscape

The virtual care market is crowded with companies focused on making the front door easier to open. TytoCare is trying to make the room behind that door more clinically useful by bringing physical examination data into virtual workflows. That creates a different competitive position than platforms built primarily around scheduling, communication, or patient engagement.

The company's Home Smart Clinic strategy reflects what health systems and payers increasingly expect from digital health vendors. They do not need another application that creates a parallel care channel. They need technology that integrates with provider workflows, supports chronic care populations, and helps clinicians make better decisions when patients are not physically in the office.

What This Signals

The financing reflects a broader investor shift in healthcare AI. Capital continues flowing into the sector, but the companies with the greatest long-term potential are likely to combine regulatory defensibility, proprietary clinical workflows, and a credible foundation of trust with providers, payers, and patients. TytoCare's combination of hardware, AI diagnostics, and care program integration aligns closely with that thesis.

The leadership transition also reflects careful timing. Pellegrini's appointment gives TytoCare an operator aligned with its next phase of growth, while the founders' continued involvement preserves the institutional knowledge and product vision that built the company. Startups often treat leadership transitions as drama. The better ones treat them as architecture.

The Bigger Industry Shift

The next phase of virtual care will not be judged by convenience alone. It will be judged by whether remote care can generate enough clinical insight to support meaningful decisions across primary care, cardiopulmonary conditions, oncology monitoring, COPD, congestive heart failure, and post-acute recovery.

TytoCare's $25M+ growth round is a bet that the physical examination can become more portable without becoming less rigorous. If that thesis proves correct, the company's work will matter beyond a single financing announcement. It will point toward a healthcare system where geography matters less, but clinical rigor continues to have the final word.